Protagonist Therapeutics (PTGX) News Today $55.34 -1.03 (-1.83%) Closing price 04:00 PM EasternExtended Trading$55.24 -0.10 (-0.18%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 10,000 SharesProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) insider Arturo Md Molina sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $57.03, for a total transaction of $570,300.00. Following the completion of the transaction, the insider now owns 83,892 shares of the company's stock, valued at approximately $4,784,360.76. The trade was a 10.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.June 11 at 8:24 PM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded by Wall Street Zen to "Hold" RatingJune 9 at 2:39 AM | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street ZenWall Street Zen raised Protagonist Therapeutics from a "sell" rating to a "hold" rating in a research note on Sunday.June 8 at 3:22 AM | marketbeat.comHennion & Walsh Asset Management Inc. Sells 6,008 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Hennion & Walsh Asset Management Inc. decreased its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 18.7% during the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 26,066 shares of the company's stock after selling 6,008 sharesJune 7, 2025 | marketbeat.comShort Interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Decreases By 13.6%Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) was the recipient of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 5,290,000 shares, a decline of 13.6% from the April 30th total of 6,120,000 shares. Based on an average daily volume of 1,250,000 shares, the days-to-cover ratio is currently 4.2 days. Currently, 9.4% of the company's stock are short sold.June 5, 2025 | marketbeat.com9 Analysts Assess Protagonist Therapeutics: What You Need To KnowJune 4, 2025 | benzinga.comProtagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Protagonist Therapeutics in a research note on Tuesday.June 3, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stake Lifted by Mackenzie Financial CorpMackenzie Financial Corp increased its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 174.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,349 shares of the company's sJune 2, 2025 | marketbeat.comProtagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia VeraJune 1, 2025 | businesswire.comWellington Management Group LLP Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Wellington Management Group LLP lifted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 3,025.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 940,077 shares of the company's stock afterJune 1, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $11.11 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 21.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 287,911 shares ofJune 1, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Stock Rating Lowered by Wall Street ZenJune 1, 2025 | americanbankingnews.comNuveen Asset Management LLC Sells 80,877 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Nuveen Asset Management LLC lowered its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 34.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 151,197 shares of the compJune 1, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street ZenWall Street Zen downgraded Protagonist Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday.June 1, 2025 | marketbeat.com340,974 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Toronto Dominion BankToronto Dominion Bank bought a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 340,974 shares of the company's stock, vaMay 30, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 21,121 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)D. E. Shaw & Co. Inc. decreased its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 78.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,704 shares of theMay 29, 2025 | marketbeat.comBank of America Corp DE Has $5.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Bank of America Corp DE grew its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 13.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 134,872 shares of the company's stock after purchasing anMay 29, 2025 | marketbeat.comProtagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancementsMay 28, 2025 | investing.comProtagonist Therapeutics (PTGX) Rose on Positive Trial OutcomeMay 27, 2025 | msn.comCache Advisors LLC Makes New $392,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Cache Advisors LLC purchased a new position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 10,143 shares of the company's stock, valued at approximately $392,000. SevMay 26, 2025 | marketbeat.comWoodline Partners LP Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Woodline Partners LP boosted its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 24.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 582,327 shares of the company's sMay 23, 2025 | marketbeat.comToronto Dominion Bank Makes New $13.16 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Toronto Dominion Bank acquired a new position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 340,974 shares of the cMay 23, 2025 | marketbeat.comMan Group plc Has $6.10 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Man Group plc boosted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 182.9% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 157,963 shares of the company's stock after purchasing an additioMay 23, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from AnalystsProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) has earned a consensus recommendation of "Buy" from the nine analysts that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and oneMay 22, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Protagonist Therapeutics in a report on Monday.May 21, 2025 | marketbeat.comSoleus Capital Management L.P. Makes New $10.62 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Soleus Capital Management L.P. purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 275,000 shares of the company's stocMay 21, 2025 | marketbeat.comDeutsche Bank AG Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Deutsche Bank AG lifted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 14.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 137,932 shares of the company's stock after acquiring an additional 17,763 shares during the perMay 21, 2025 | marketbeat.comRTW Investments LP Has $212.24 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)RTW Investments LP raised its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 5,498,545 shares of the company's stock after purchasing an additMay 18, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Northern Trust CorpNorthern Trust Corp grew its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 8.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 628,580 shares of the company's stMay 15, 2025 | marketbeat.comJefferies Financial Group Inc. Has $57.50 Million Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Jefferies Financial Group Inc. trimmed its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 17.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,489,495 shares of the compaMay 13, 2025 | marketbeat.comCrestline Management LP Invests $489,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Crestline Management LP bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 12,681 shares of the company's stock, valued at approximately $489,000. SeveralMay 13, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Algert Global LLCAlgert Global LLC lowered its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 84.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 17,720 shares of the company's stock after selling 97,959 shares during theMay 13, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for PTGXProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Equities researchers at HC Wainwright reduced their Q2 2025 EPS estimates for Protagonist Therapeutics in a research report issued on Wednesday, May 7th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings ofMay 13, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 105,654 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Driehaus Capital Management LLC lowered its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 23.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 339,698 shares of the company's stockMay 12, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for PTGX EarningsProtagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) - Wedbush increased their Q2 2025 earnings per share estimates for shares of Protagonist Therapeutics in a note issued to investors on Wednesday, May 7th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($0.59) per shaMay 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Farallon Capital Management LLCFarallon Capital Management LLC boosted its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,930,006 shares of the company's stock after buying an additional 6May 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by AQR Capital Management LLCAQR Capital Management LLC increased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 9.4% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 150,097 shares of the company's stocMay 11, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Purchases 8,576 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)The Manufacturers Life Insurance Company lifted its holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 7.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 124,341 shares of the company's stock after puMay 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (PTGX): Among the Best Cancer Stocks to Invest in for Long-Term GainMay 9, 2025 | insidermonkey.comDeep Track Capital LP Invests $38.60 Million in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Deep Track Capital LP purchased a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,000,000 shares of the company's stock, valued atMay 9, 2025 | marketbeat.comProtagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?May 8, 2025 | finance.yahoo.comBraidwell LP Makes New Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Braidwell LP bought a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 20,109 shares of the company's stock, valued at approximately $776May 8, 2025 | marketbeat.comBellevue Group AG Purchases 11,372 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Bellevue Group AG increased its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 92.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,718 shares of the company's stock after acqMay 7, 2025 | marketbeat.comFreestone Grove Partners LP Buys New Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Freestone Grove Partners LP purchased a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 6,644 sharMay 7, 2025 | marketbeat.comProtagonist Therapeutics: Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 6, 2025 | finanznachrichten.deProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Increased by BVF Inc. ILBVF Inc. IL lifted its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,900,015 shares of the company's stock after purchasing anMay 6, 2025 | marketbeat.comVoya Investment Management LLC Sells 31,225 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Voya Investment Management LLC trimmed its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 27.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 82,627 shares of theMay 5, 2025 | marketbeat.comTower Research Capital LLC TRC Boosts Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Tower Research Capital LLC TRC raised its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 1,946.9% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 7,369 shares of the company's stock after buying an additionMay 5, 2025 | marketbeat.com683 Capital Management LLC Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)683 Capital Management LLC decreased its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 2.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 410,00May 4, 2025 | marketbeat.comMarshall Wace LLP Lowers Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)Marshall Wace LLP trimmed its holdings in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 93.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 19,716 shares of the company's stMay 4, 2025 | marketbeat.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼0.951.01▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼86▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Moderna News Ascendis Pharma A/S News Viatris News Qiagen News Blueprint Medicines News Roivant Sciences News Revolution Medicines News BridgeBio Pharma News Elanco Animal Health News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PTGX Stock Free PTGX Stock Alerts